Glucagon News and Research

RSS

MIT develops implantable device to automatically release emergency glucagon

For people with Type 1 diabetes, developing hypoglycemia, or low blood sugar, is an ever-present threat. When glucose levels become extremely low, it creates a life-threatening situation for which the standard treatment of care is injecting a hormone called glucagon.

9 Jul 2025

Innovative genome editing approach could be the key to lifelong effective weight management

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.

9 Jul 2025

New study identifies factors linked to successful weight loss using GLP-1RAs

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).

9 Jul 2025

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.

7 Jul 2025

$Newer, more effective diabetes drugs reach only a fraction of patients$

Newer, more effective diabetes drugs reach only a fraction of patients

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

1 Jul 2025

Coffee’s hidden compounds could help fight type 2 diabetes

A comprehensive review of nearly 150 studies reveals that coffee polyphenols may help regulate blood sugar and reduce inflammation linked to type 2 diabetes. However, most evidence comes from preclinical research, and robust clinical trials are needed to confirm benefits.

29 Jun 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

New pretreatment method boosts islet transplant survival in diabetes

A pretreatment step could help transplanted pancreatic islets survive longer in patients with type 1 diabetes, according to a new preclinical study from Weill Cornell Medicine investigators. One combination of small molecules extended the cells' lives in female mice, and adding two molecules to the mixture boosted cell survival in male mice.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

23 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

Men lose more weight than women on the keto diet, new study reveals why

Men lose more weight than women on a ketogenic diet, according to a comprehensive review in Frontiers in Nutrition. Sex differences in hormones, metabolism, and fat distribution influence the effectiveness of the ketogenic diet for obesity.

22 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

Oxytocin stimulates pancreatic hormones to improve insulin secretion

A new research paper was published in Aging (Aging-US) Volume 17, Issue 5, on May 1, 2025, titled "Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets."

18 Jun 2025

Could a diabetes drug be the key to stopping Alzheimer’s?

Investigating tirzepatide's role in Alzheimer's reveals its potential to improve brain function and reduce inflammation, linking diabetes and neurodegeneration.

17 Jun 2025

Estrogen-responsive cells found to heighten gut pain in females

Researchers uncovered how estrogen heightens gut sensitivity in females by activating PYY-secreting L-cells, which stimulate serotonin release from EC cells. This paracrine circuit intensifies pain signaling and may explain the sex bias in conditions like IBS.

16 Jun 2025

New data reveals insights into cancer and cardiovascular safety of JAK inhibitors

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle.

12 Jun 2025

Tufts researchers design new generation of weight loss medications

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks.

11 Jun 2025